SE527639C2 - Alkylsubstituerade indolokinoxaliner - Google Patents

Alkylsubstituerade indolokinoxaliner

Info

Publication number
SE527639C2
SE527639C2 SE0401555A SE0401555A SE527639C2 SE 527639 C2 SE527639 C2 SE 527639C2 SE 0401555 A SE0401555 A SE 0401555A SE 0401555 A SE0401555 A SE 0401555A SE 527639 C2 SE527639 C2 SE 527639C2
Authority
SE
Sweden
Prior art keywords
formula
compound
alkyl
compounds
indolo
Prior art date
Application number
SE0401555A
Other languages
English (en)
Swedish (sv)
Other versions
SE0401555L (sv
SE0401555D0 (sv
Inventor
Jan Bergman
Robert Engqvist
Bengt Gerdin
Ingemar Kihlstroem
Ulf Bjoerklund
Original Assignee
Oxypharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxypharma Ab filed Critical Oxypharma Ab
Priority to SE0401555A priority Critical patent/SE527639C2/sv
Publication of SE0401555D0 publication Critical patent/SE0401555D0/xx
Priority to AT05742482T priority patent/ATE462707T1/de
Priority to AU2005254919A priority patent/AU2005254919B2/en
Priority to DK05742482.2T priority patent/DK1756111T3/da
Priority to PCT/SE2005/000718 priority patent/WO2005123741A1/en
Priority to BRPI0512086-1A priority patent/BRPI0512086A/pt
Priority to ES05742482T priority patent/ES2342946T3/es
Priority to SI200531030T priority patent/SI1756111T1/sl
Priority to JP2007516422A priority patent/JP5038891B2/ja
Priority to ZA200700358A priority patent/ZA200700358B/xx
Priority to DE602005020283T priority patent/DE602005020283D1/de
Priority to US11/143,935 priority patent/US7589093B2/en
Priority to PL05742482T priority patent/PL1756111T3/pl
Priority to EP05742482A priority patent/EP1756111B1/de
Priority to NZ551780A priority patent/NZ551780A/en
Priority to PT05742482T priority patent/PT1756111E/pt
Priority to RU2007101497/04A priority patent/RU2369609C2/ru
Priority to MXPA06014170A priority patent/MXPA06014170A/es
Priority to CN200580019227XA priority patent/CN1976934B/zh
Priority to CA2568592A priority patent/CA2568592C/en
Publication of SE0401555L publication Critical patent/SE0401555L/sv
Publication of SE527639C2 publication Critical patent/SE527639C2/sv
Priority to IL179171A priority patent/IL179171A/en
Priority to NO20070289A priority patent/NO20070289L/no
Priority to US12/496,261 priority patent/US8084453B2/en
Priority to CY20101100598T priority patent/CY1110145T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
SE0401555A 2004-06-17 2004-06-17 Alkylsubstituerade indolokinoxaliner SE527639C2 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE0401555A SE527639C2 (sv) 2004-06-17 2004-06-17 Alkylsubstituerade indolokinoxaliner
CA2568592A CA2568592C (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines
PL05742482T PL1756111T3 (pl) 2004-06-17 2005-05-18 Alkilo-podstawione indolochinoksaliny
NZ551780A NZ551780A (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines
DK05742482.2T DK1756111T3 (da) 2004-06-17 2005-05-18 Alkylsubstituerede indoloquinoxaliner
PCT/SE2005/000718 WO2005123741A1 (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines
BRPI0512086-1A BRPI0512086A (pt) 2004-06-17 2005-05-18 composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos
ES05742482T ES2342946T3 (es) 2004-06-17 2005-05-18 Indoloquinoxalinas sustituidas con alquilo.
SI200531030T SI1756111T1 (sl) 2004-06-17 2005-05-18 Alkilno substituirani indolokinoksalini
JP2007516422A JP5038891B2 (ja) 2004-06-17 2005-05-18 アルキル置換されたインドロキノキサリン化合物
ZA200700358A ZA200700358B (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines
DE602005020283T DE602005020283D1 (de) 2004-06-17 2005-05-18 Alkylsubstituierte indolochinoxaline
US11/143,935 US7589093B2 (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines
AT05742482T ATE462707T1 (de) 2004-06-17 2005-05-18 Alkylsubstituierte indolochinoxaline
EP05742482A EP1756111B1 (de) 2004-06-17 2005-05-18 Alkylsubstituierte indolochinoxaline
AU2005254919A AU2005254919B2 (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines
PT05742482T PT1756111E (pt) 2004-06-17 2005-05-18 Indoloquinoxalinas com radicais alquilo como substituintes
RU2007101497/04A RU2369609C2 (ru) 2004-06-17 2005-05-18 Алкилзамещенные индолхиноксалины
MXPA06014170A MXPA06014170A (es) 2004-06-17 2005-05-18 Indoloquinoxalinas de alquilo sustituido.
CN200580019227XA CN1976934B (zh) 2004-06-17 2005-05-18 烷基取代的吲哚并喹喔啉
IL179171A IL179171A (en) 2004-06-17 2006-11-09 Inodolo [b – 3,2] Process for the preparation of quinoxylins converted into alkyl, and pharmaceutical preparations containing them
NO20070289A NO20070289L (no) 2004-06-17 2007-01-16 Alkylsubstituerte indolokinoksaliner
US12/496,261 US8084453B2 (en) 2004-06-17 2009-07-01 Alkyl substituted indoloquinoxalines
CY20101100598T CY1110145T1 (el) 2004-06-17 2010-06-29 Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401555A SE527639C2 (sv) 2004-06-17 2004-06-17 Alkylsubstituerade indolokinoxaliner

Publications (3)

Publication Number Publication Date
SE0401555D0 SE0401555D0 (sv) 2004-06-17
SE0401555L SE0401555L (sv) 2005-12-18
SE527639C2 true SE527639C2 (sv) 2006-05-02

Family

ID=32710074

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401555A SE527639C2 (sv) 2004-06-17 2004-06-17 Alkylsubstituerade indolokinoxaliner

Country Status (23)

Country Link
US (2) US7589093B2 (de)
EP (1) EP1756111B1 (de)
JP (1) JP5038891B2 (de)
CN (1) CN1976934B (de)
AT (1) ATE462707T1 (de)
AU (1) AU2005254919B2 (de)
BR (1) BRPI0512086A (de)
CA (1) CA2568592C (de)
CY (1) CY1110145T1 (de)
DE (1) DE602005020283D1 (de)
DK (1) DK1756111T3 (de)
ES (1) ES2342946T3 (de)
IL (1) IL179171A (de)
MX (1) MXPA06014170A (de)
NO (1) NO20070289L (de)
NZ (1) NZ551780A (de)
PL (1) PL1756111T3 (de)
PT (1) PT1756111E (de)
RU (1) RU2369609C2 (de)
SE (1) SE527639C2 (de)
SI (1) SI1756111T1 (de)
WO (1) WO2005123741A1 (de)
ZA (1) ZA200700358B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE529777C2 (sv) * 2006-01-23 2007-11-20 Vironova Ab Nya föreningar och användning därav
JP5454750B2 (ja) 2008-03-05 2014-03-26 東洋製罐株式会社 缶詰の内圧検査方法及びその装置
DE602008001795D1 (de) 2008-04-30 2010-08-26 Univ Duisburg Essen IndolÄ2,3-bÜ-, IndenÄ1,2-bÜ- und IndenÄ2,1-bÜpyridoÄ2,3-fÜ Quinoxalin-3-Carboxylsäuren und Ester, Verfahren zu ihrer Herstellung und ihre Verwendung als Antivirus- und Antitumormittel
EP2489354A1 (de) 2011-02-18 2012-08-22 Vironova AB Pharmazeutische Formulierung enthaltend B220 zur topischen Behandlung von Herpes
CN103211960B (zh) * 2012-01-18 2017-10-13 金士力佳友(天津)有限公司 具有降血糖作用的中药组合物、其应用及制备方法
EA201500942A1 (ru) * 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
EP4164649A1 (de) 2020-06-10 2023-04-19 Cyxone AB Neue verwendung von rabeximod
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
AU2021344650A1 (en) 2020-09-21 2023-05-18 Vironova Medical Ab Thionoester-derivative of rabeximod for the treatment of inflammatory and autoimmune disorders
US11643415B1 (en) 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504862C2 (sv) * 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US6333327B2 (en) * 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis

Also Published As

Publication number Publication date
RU2007101497A (ru) 2008-07-27
AU2005254919A1 (en) 2005-12-29
CN1976934A (zh) 2007-06-06
US8084453B2 (en) 2011-12-27
CY1110145T1 (el) 2015-01-14
IL179171A0 (en) 2007-03-08
WO2005123741A1 (en) 2005-12-29
JP2008502676A (ja) 2008-01-31
RU2369609C2 (ru) 2009-10-10
AU2005254919B2 (en) 2011-07-21
US20100009999A1 (en) 2010-01-14
CA2568592C (en) 2012-10-30
JP5038891B2 (ja) 2012-10-03
CN1976934B (zh) 2013-05-29
CA2568592A1 (en) 2005-12-29
US20050288296A1 (en) 2005-12-29
ZA200700358B (en) 2008-07-30
SI1756111T1 (sl) 2010-08-31
ATE462707T1 (de) 2010-04-15
IL179171A (en) 2012-12-31
PL1756111T3 (pl) 2010-08-31
BRPI0512086A (pt) 2008-02-06
US20110086859A9 (en) 2011-04-14
NO20070289L (no) 2007-01-16
EP1756111A1 (de) 2007-02-28
SE0401555L (sv) 2005-12-18
PT1756111E (pt) 2010-06-01
DK1756111T3 (da) 2010-07-12
NZ551780A (en) 2010-05-28
ES2342946T3 (es) 2010-07-19
DE602005020283D1 (de) 2010-05-12
US7589093B2 (en) 2009-09-15
MXPA06014170A (es) 2007-05-09
SE0401555D0 (sv) 2004-06-17
EP1756111B1 (de) 2010-03-31

Similar Documents

Publication Publication Date Title
US8084453B2 (en) Alkyl substituted indoloquinoxalines
JP5419892B2 (ja) キナゾリンおよび関連する複素環式化合物、ならびにそれらの治療的使用
CN105492426B (zh) N‑(4‑羟基‑4‑甲基‑环己基)‑4‑苯基‑苯磺酰胺和n‑(4‑羟基‑4‑甲基‑环己基)‑4‑(2‑吡啶基)苯磺酰胺和其治疗性用途
JPH06220026A (ja) 置換シクロプロピルアミノ−１，３，５−トリアジン化合物
JP2013506716A (ja) クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法
HUT68445A (en) Antiviral nucleoside analogues
CN107207431A (zh) Ca2+释放激活的Ca2+（CRAC）通道的调节剂及其药物用途
US20210040034A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
JP2865255B2 (ja) １，２，３，４，１０，１４ｂ‐ヘキサヒドロジベンゾ〔ｃ，ｆ〕ピラジノ〔１，２‐ａ〕アゼピノ誘導体及び１０‐アザ，１０‐オキサ及び１０‐チア類似体
EP0052296B1 (de) Als Heilmittel für Immunokrankheiten anwendbare Glutaminderivate, Verfahren zu deren Herstellung und Zusammensetzungen, die die obengenannten Derivate enthalten
JPS59141559A (ja) ラクタムペプチド及びその製造方法並びに該ペプチドを含有する医薬
US7247630B2 (en) Uses of tricyclic compounds
US12377070B2 (en) Substituted sulfoximine derivatives
US8247422B2 (en) Use of condensed pyrimidine derivatives for the treatment of rheumatoid arthritis
JP3702382B2 (ja) ＮＦ−κＢ活性化阻害剤
JP2798628B2 (ja) 癲癇治療用の５−アミノカルボニル−５Ｈ−ジベンゾ［ａ，ｄ］シクロヘプテン−５，１０−イミン
CN113637019A (zh) 一种选择性jak1抑制剂化合物及其制备方法和用途
RU2602504C1 (ru) Гидрогалогениды 11-[(4-трет-бутилфенокси)этил]- и 11-бензилзамещённых 2,3,4,5-тетрагидро[1,3]диазепино[1,2-a]бензимидазола, обладающие альфа-глюкозидаза ингибирующей активностью
ES2246090T3 (es) Oxo-piridoimidazol-carboxamidas: ligandos del receptor cerebral gaba.
JPH0717647B2 (ja) テトラヒドロピリジン誘導体

Legal Events

Date Code Title Description
NUG Patent has lapsed